论著·机制探索

Sugen低氧诱导肺动脉高压小鼠模型中免疫细胞亚群的动态变化

  • 刘杰 ,
  • 薛鑫 ,
  • 郭煜 ,
  • 高振强 ,
  • 张寒晓 ,
  • 张牧之 ,
  • 隆寰宇 ,
  • 吕佳璐 ,
  • 许蒙雨 ,
  • 贾玉峰 ,
  • 崔烨 ,
  • 王炜 ,
  • 孙英 ,
  • 王蕾
展开
  • 1.首都医科大学基础医学院免疫学系 (北京 100069 )
    2.西安交通大学第二附属医院呼吸与危重症医学科 (陕西 西安 710004 )
    3.北京大学第三医院呼吸与危重症医学科 (北京 100191 )

收稿日期: 2025-11-06

  网络出版日期: 2026-04-28

基金资助

国家自然科学基金项目(82202014);北京市教育委员会科研计划一般项目(KM202310025029);临港实验室“求索杰出青年计划”开放课题(LG-QS-202205-08)

Dynamic changes of immune cell subsets in a mouse model of Sugen-hypoxia-induced pulmonary hypertension

  • Jie LIU ,
  • Xin XUE ,
  • Yu GUO ,
  • Zhenqiang GAO ,
  • Hanxiao ZHANG ,
  • Muzhi ZHANG ,
  • Huanyu LONG ,
  • Jialu Lü ,
  • Mengyu XU ,
  • Yufeng JIA ,
  • Ye CUI ,
  • Wei WANG ,
  • Ying SUN ,
  • Lei WANG
Expand
  • 1.Department of Immunology,School of Basic Medical Sciences,Capital Medical University,Beijing 100069,Beijing,China
    2.Department of Respiratory and Critical Care Medicine,the Second Affiliated Hospital of Xi'an Jiaotong University,Shaanxi 710004,Xi'an,China
    3Department of Respiratory and Critical Care Medicine,Peking University Third Hospital,Beijing 100191,Beijing,China

Received date: 2025-11-06

  Online published: 2026-04-28

摘要

目的 探讨Sugen低氧(Sugen-hypoxia,SuHx)诱导的肺动脉高压(pulmonary hypertension,PH)小鼠模型中免疫细胞亚群的动态变化。 方法 建立SuHx-PH小鼠模型(皮下注射Sugen5416后联合低氧处理),分别于建模前及建模后1(h1w)、2(h2w)、3(h3w)、4(h4w)周收集小鼠肺组织,采用流式细胞术检测CD45+免疫细胞中T细胞、B细胞、巨噬细胞、嗜酸性粒细胞(EOS)、中性粒细胞(Neu)、自然杀伤(NK)细胞及固有淋巴细胞(ILC)等免疫细胞亚群的比例变化。 结果 与对照组相比,SuHx模型小鼠免疫细胞亚群呈现显著时序性变化。其中,CD11c+F4/80+总巨噬细胞、间质巨噬细胞(IM,SIGLECF?)随着建模时间的持续呈现显著的下降趋势;肺泡巨噬细胞(AM,SIGLECF+)的细胞水平持续上升(P < 0.05);EOS、ILC、Neu以及CD4+T细胞呈现显著的波动趋势,组间比较差异有统计学意义(P < 0.05)。 结论 SuHx-PH 小鼠肺组织内免疫细胞亚群比例呈现显著时序性改变,提示不同免疫细胞在PH病程发展中可能发挥阶段特异性作用:早期Neu启动急性炎症反应,EOS发挥抗炎保护作用,巨噬细胞亚群发生表型转换;中期 适应性免疫激活,CD4+T细胞参与血管重构调控,巨噬细胞进一步推动纤维化微环境形成;晚期Neu再次升高加剧炎症恶化,EOS保护作用减弱,ILC促进血管闭塞性病变。本研究为深入理解PH 免疫炎症机制及寻找潜在免疫干预靶点提供了依据。

本文引用格式

刘杰 , 薛鑫 , 郭煜 , 高振强 , 张寒晓 , 张牧之 , 隆寰宇 , 吕佳璐 , 许蒙雨 , 贾玉峰 , 崔烨 , 王炜 , 孙英 , 王蕾 . Sugen低氧诱导肺动脉高压小鼠模型中免疫细胞亚群的动态变化[J]. 实用医学杂志, 2026 , 42(8) : 1407 -1414 . DOI: 10.3969/j.issn.1006-5725.2026.08.014

Abstract

Objective To investigate the dynamic changes of immune cell subsets in a mouse model of pulmonary hypertension (PH) induced by Sugen-hypoxia (SuHx). Methods A SuHx-PH mouse model was established through intraperitoneal injection of Sugen 5416, followed by exposure to hypoxia. Mouse lung tissues were collected prior to modeling and at 1 week (h1w), 2 weeks (h2w), 3 weeks (h3w), and 4 weeks (h4w) post-modeling. Flow cytometry was employed to detect the proportional alterations of immune cell subsets (including T cells, B cells, macrophages, eosinophils (EOS), neutrophils (Neu), natural killer (NK) cells, and innate lymphoid cells (ILCs) within CD45+ immune cells. Results Compared with the control group, the immune cell subsets in SuHx model mice demonstrated significant temporal changes. Among these, the total CD11c+F4/80+ macrophages and interstitial macrophages (IM, SIGLECF-) showed a significant decreasing tendency as the modeling time progressed; the cell levels of alveolar macrophages (AM, SIGLECF+) continuously increased (P < 0.05); EOS, ILCs, Neu, and CD4+T cells displayed a significant fluctuating pattern, with significant differences between groups (P < 0.05). Conclusions The proportions of immune cell subsets in the lung tissues of SuHx-PH mice exhibit significant temporal changes, indicating that different immune cells may play stage-specific roles in the progression of PH. This study offers a foundation for a more in-depth understanding of the immunoinflammatory mechanism of PH and the identification of potential immune intervention targets.

参考文献

[1] TUDER R M. Pulmonary vascular remodeling in pulmonary hypertension[J]. Cell Tissue Res, 2017, 367(3): 643-649. doi:10.1007/s00441-016-2539-y .
[2] 罗志梅, 刘虹延, 孙得胜. 一种肺血管基因敲减动物模型的构建及在肺动脉高压中的运用[J]. 实用医学杂志, 2023, 39(4): 404-409. doi:10.3969/j.issn.1006-5725.2023.04.003 .
[3] 张嘉莹, 樊勇, 张卓莉. 肺动脉高压发病机制中的肺血管重塑[J]. 中华临床免疫和变态反应杂志, 2023, 17(1): 50-55. doi:10.3969/j.issn.1673-8705.2023.01.010 .
[4] 徐明艳, 韩校鹏, 刘英丽, 等. 慢性阻塞性肺疾病急性加重期并发肺动脉高压的危险因素[J]. 实用医学杂志, 2022, 38(19): 2467-2471.doi:10.3969/j.issn.1006-5725.2022.19.017 .
[5] ZAWIA A, ARNOLD N D, WEST L, et al. Altered macrophage polarization induces experimental pulmonary hypertension and is observed in patients with pulmonary arterial hypertension[J]. Arterioscler Thromb Vasc Biol, 2021, 41(1): 430-445. doi:10.1161/ATVBAHA.120.314639 .
[6] LI C, LIU P, SONG R, et al. Immune cells and autoantibodies in pulmonary arterial hypertension[J]. Acta Biochim Biophys Sin, 2017, 49(12): 1047-1057. doi:10.1093/abbs/gmx095 .
[7] TARASEVICIENE-STEWART L, KASAHARA Y, ALGER L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension[J]. FASEB J, 2001, 15(2): 427-438. doi:10.1096/fj.00-0343com .
[8] 陈子宜,孙红燕,康品方,等.肺动脉高压动物实验模型的研究进展[J/OL].实验动物与比较医学,1-18[2026-03-02]..
[9] COSSARIZZA A, CHANG H D, RADBRUCH A, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)[J]. Eur J Immunol, 2019, 49(10): 1457-1973. doi:10.1002/eji.201970107 .
[10] SORKHDINI P, KLUBOCK-SHUKLA K, SHETH S, et al. Type 2 innate immunity promotes the development of pulmonary fibrosis in Hermansky-Pudlak syndrome[J]. JCI Insight, 2024, 9(22): e178381. doi:10.1172/jci.insight.178381 .
[11] IKUTANI M, SHIMIZU S, OKADA K, et al. Characterization of long-term interleukin-33 administration as an animal model of pulmonary arterial hypertension[J]. Biochem Biophys Res Commun, 2024, 734: 150750. doi:10.1016/j.bbrc.2024.150750 .
[12] LI N, LI Q, BAI J, et al. The multiple organs insult and compensation mechanism in mice exposed to hypobaric hypoxia[J]. Cell Stress Chaperones, 2020, 25(5): 779-791. doi:10.1007/s12192-020-01117-w .
[13] SERHAN C N, BRAIN S D, BUCKLEY C D, et al. Resolution of inflammation: State of the art, definitions and terms[J]. FASEB J, 2007, 21(2): 325-332. doi:10.1096/fj.06-7227rev .
[14] KUANG M, CHEN Y, XING Y, et al. Echocardiographic evaluation of right heart failure which might be associated with DNA damage response in SU5416-hypoxia induced pulmonary hypertension rat model[J]. Respir Res, 2023, 24(1): 202. doi:10.1186/s12931-023-02501-7 .
[15] 秦崇, 潘磊, 李佳, 等. 低压低氧肺动脉高压形成中CD4+T细胞亚群的变化[J]. 标记免疫分析与临床, 2024, 31(9): 1580-1588. doi:10.11748/bjmy.issn.1006-1703.2024.09.003 .
[16] AYASS M A, TRIPATHI T, ZHU K, et al. T helper (Th) cell profiles and cytokines/chemokines in characterization, treatment, and monitoring of autoimmune diseases[J]. Methods, 2023, 220: 115-125. doi:10.1016/j.ymeth.2023.11.003 .
[17] TAMOSIUNIENE R, MANOUVAKHOVA O, MESANGE P, et al. Dominant role for regulatory T cells in protecting females against pulmonary hypertension[J]. Circ Res, 2018, 122(12): 1689-1702. doi:10.1161/CIRCRESAHA.117.312058 .
[18] SHU T, ZHANG J, ZHOU Y, et al. Eosinophils protect against pulmonary hypertension through 14-HDHA and 17-HDHA[J]. Eur Respir J, 2023, 61(3): 2200582. doi:10.1183/13993003.00582-2022 .
[19] 陈睿迪, 王炜, 张若旸. 巨噬细胞在间质性肺疾病相关肺动脉高压中的作用[J]. 微生物学免疫学进展, 2025, 53(4): 87-93. doi:10.13309/j.cnki.pmi.2025.04.014 .
[20] SHAPOURI-MOGHADDAM A, MOHAMMADIAN S, VAZINI H, et al. Macrophage plasticity, polarization, and function in health and disease[J]. J Cell Physiol, 2018, 233(9): 6425-6440. doi:10.1002/jcp.26429 .
[21] ZHANG M Q, WANG C C, PANG X B, et al. Role of macrophages in pulmonary arterial hypertension[J]. Front Immunol, 2023, 14: 1152881. doi:10.3389/fimmu.2023.1152881 .
[22] FLORENTIN J, COPPIN E, VASAMSETTI S B, et al. Inflammatory macrophage expansion in pulmonary hypertension depends upon mobilization of blood-borne monocytes[J]. J Immunol, 2018, 200(10): 3612-3625. doi:10.4049/jimmunol.1701287 .
[23] AL-QAZAZI R, LIMA P D A, PRISCO S Z, et al. Macrophage-NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2022, 206(5): 608-624. doi:10.1164/rccm.202110-2274OC .
[24] DANG B, GAO Q, ZHANG L, et al. The glycolysis/HIF-1α axis defines the inflammatory role of IL-4-primed macrophages[J]. Cell Rep, 2023, 42(5): 112471. doi:10.1016/j.celrep.2023.112471 .
[25] NIE X, SHEN C, TAN J, et al. Periostin: A potential therapeutic target for pulmonary hypertension?[J]. Circ Res, 2020, 127(9): 1138-1152. doi:10.1161/CIRCRESAHA.120.316943 .
文章导航

/